Home > Media > Details
Angitia Announces that NMPA has Granted Phase III IND Approval for AGA111, a Drug Candidate for Spinal Fusion

Guangzhou, China, and Woodland Hills, California, USA –16 Oct 2023: Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced today that National Medicinal Product Administration (NMPA) has approved Angitia Biopharmaceuticals’ Investigational New Drug (IND) application of the Phase III study for AGA111. Angitia has previously announced the encouraging results from AGA111’s Phase I/II trial, which demonstrated excellent safety and preliminary efficacy in lumbar interbody fusion.

The Phase III, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.

“We are delighted to share this exciting news, which is an important milestone for Angitia, as our first program to initiate a pivotal trial. Based on the encouraging Phase I/II study results, we believe that AGA111 has the potential to significantly accelerate bony fusion, reduce nonunion rate, and meaningfully improve patient outcomes.” said David Ke, M.D., Founder and CEO of Angitia.

About Spinal Fusion

Spinal fusion is a widely used surgical treatment for spinal disorders. The incidence of nonunion after spinal fusion surgery has been reported as high as 56% in the lumbar spine [1]. A large case report shows that up to 23.6% of spinal revision surgery is related to nonunion [2]. Nonunion of the spine can have significant adverse impact on postoperative function and clinical outcomes [3].

About Angitia Biopharmaceuticals

Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the unmet medical needs of patients with serious musculoskeletal diseases. With the team’s experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need. Founded in 2018, Angitia has operations in Guangzhou, China and in Woodland Hills, California, USA.

Learn more at and follow us on LinkedIn.


1.    Lee C, Dorcil J, Radomisli TE. Nonunion of the spine: a review. Clin Orthop Relat Res. 2004;(419):71-75. doi:10.1097/00003086-200402000-00012

2.    Raizman NM, O'Brien JR, Poehling-Monaghan KL, Yu WD. Pseudarthrosis of the spine. J Am Acad Orthop Surg. 2009;17(8):494-503. doi:10.5435/00124635-200908000-00003

3.    Tsutsumimoto T, Shimogata M, Yoshimura Y, Misawa H. Union versus nonunion after posterolateral lumbar fusion: a comparison of long-term surgical outcomes in patients with degenerative lumbar spondylolisthesis. Eur Spine J. 2008;17(8):1107-1112. doi:10.1007/s00586-008-0695-9

Forward-Looking Statement

This press release is prepared by Angitia (the “Company", “We”) for informational purposes only. Forward-looking statements include all statements that are not historical facts and in some cases can be identified by terms such as “anticipate,” “expect,” “intend”, “plan”, “believe”, “continue”, “could”, “potential”, “may”, “will”, “goal” or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words.

These forward-looking statements are based on the current projects, expectations, assumptions, and understandings of the Company with respect to future events as of the date these statements are made. These statements are not a guarantee or warranty of future developments or otherwise. 

These statements involve substantial known and unknown risks, uncertainties, and other factors that are beyond the Company’s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.